

Defiance Hospital



60
PUBLIC/PDR

February 14, 1997

030-09534

U.S. Nuclear Regulatory Commission, Region III
801 Warrenville Road
Lisle, Illinois 60532-4351

RE: License No. 34-15654-01

To whom it may concern:

We are requesting an amendment to our current U.S. Nuclear Regulatory Commission Materials License. We wish to add the following radiologists as authorized users for material groups 35.100 and 35.200:

Ronald A. Siwik, M.D.
Juergen J. Lehmann, M.D.

Dr. Siwik was previously on U.S. NRC Materials License # 34-17932-01 from Meridia Euclid Hospital. Dr. Lehmann was previously on NRC Materials License # 13-01629-03 from Caylor-Nickel Hospital, Inc. Both of these physicians are in full clinical practice and maintain continuing medical education in accordance with ACR guidelines.

Enclosed you will find our amendment fee of \$ 440.00.

If you have any questions, please feel free to contact me, at 419-783-6955, ext.5309.

Sincerely,

Terry Jacobs

Terry Jacobs
Director of Radiology

Enclosures

9703060315 970214
PDR ADOCK 03009534
C PDR



060057

Pm. 2-14-97

1206 East Second Street - Defiance, Ohio 43512 - 419/783-6955 - Fax 419/783-6967

RECEIVED

FEB 18 1997

REGION III ml

FEB 18 1997

31
DTH

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438) and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 39, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

396193

Licensee

1. Caylor-Nickel Hospital, Inc.

2. 1 Caylor-Nickel Square
Bluffton, IN 46714

In accordance with letter dated
December 13, 1993

3. License number 13-01629-03 is amended in
its entirety to read as follows:

4. Expiration date October 31, 1994

5. Docket or
Reference No 030-01596

6. Byproduct, source, and/or
special nuclear material

7. Chemical and/or physical
form

8. Maximum amount that licensee
may possess at any one time
under this license

A. Any byproduct
material identified
in 10 CFR 35.100

A. Any
radiopharmaceutical
identified in 10 CFR
35.100

A. As needed

B. Any byproduct
material identified
in 10 CFR 35.200

B. Any
radiopharmaceutical
identified in 10 CFR
35.200

B. As needed

C. Any byproduct
material identified
in 10 CFR 35.300

C. Any
radiopharmaceutical
identified in 10 CFR
35.300 (excluding
treatment of thyroid
carcinoma)

C. As needed (not to
exceed 1 curie of
I-131)

D. Any byproduct
material identified
in 10 CFR 35.500

D. Sealed sources
identified in 10 CFR
35.500

D. As needed

E. Any byproduct
material identified
in 10 CFR 31.11

E. Prepackaged Kits

E. As needed

9. Authorized Use:

A. Medical use described in 10 CFR 35.100 10207

B. Medical use described in 10 CFR 35.200.

C. Medical use described in 10 CFR 35.300 (excluding treatment of thyroid carcinoma)

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number

13-01629-03

Docket or Reference number

030-01596

Amendment No. 46

D. Medical use described in 10 CFR 35.500 in devices which have been evaluated and approved for licensing purposes by the U.S. Nuclear Regulatory Commission or an Agreement State.

E. In vitro studies.

CONDITIONS

10. Location of Use: One Cayton-Nickel Square, Bluffton, IN 46714

11. Radiation Safety Officer: Otto J. N. Kunst, M.D.

12. Authorized Users:

A. Steve C. Cuff, M.D., for material in 10 CFR 35.100, 35.200, 35.300 (excluding treatment of thyroid carcinoma), 35.500, and 31.11.

B. Otto J. N. Kunst, M.D., for material in 10 CFR 35.100, 35.200, 35.500, and 31.11.

C. Juergen J. Lehmann, M.D., for material in 10 CFR 35.100, 35.200, 35.300 (excluding treatment of thyroid carcinoma), 35.500, and 31.11.

13. Pursuant to Title 10, Chapter 1, Code of Federal Regulations, Part 40, "Domestic Licensing of Source Material, the licensee is authorized to possess, use, transfer, and import up to 999 kilograms of depleted uranium contained as shielding material in the molybdenum-99/technetium-99m generators authorized by this license.

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated July 21, 1989.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date JAN 11 1994

By

Materials Licensing Section, Region III

COPY

MATERIALS LICENSE

Amendment No. 11
CORRECTED COPY

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 39, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p>Licensee</p> <p>1. Meridia Euclid Hospital</p> <p>2. 18901 Lake Shore Boulevard Euclid, OH 44119</p>		<p>In accordance with application dated February 21, 1994</p> <p>3. License number 34-17932-01 is renewed in its entirety to read as follows:</p>	
		<p>4. Expiration date April 30, 1999</p>	
		<p>5. Docket or Reference No 030-13671</p>	
6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100	A. As needed	
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200	B. As needed	
C. Any byproduct material identified in 10 CFR 35.300	C. Any radiopharmaceutical identified in 10 CFR 35.300	C. As needed	
D. Any byproduct material identified in 10 CFR 31.11	D. Prepackaged Kits	D. As needed	
9. Authorized Use:			
A. Medical use described in 10 CFR 35.100.			
B. Medical use described in 10 CFR 35.200.			
C. Medical use described in 10 CFR 35.300.			
D. In vitro studies.			

CONDITIONS

10. Location of Use: Meridia Euclid Hospital, 18901 Lake Shore Boulevard, Euclid, Ohio.
11. Radiation Safety Officer: Bon Chul Koo, M.D.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number

34-17932-01

Docket or Reference number

030-13671

Amendment No. 11

CORRECTED COPY

12. Authorized Users:

- A. Howard J. Klein, M.D., for material listed in 10 CFR 35.100, 35.200, 35.300 and in vitro studies.
- B. Glenn F. Sykora, M.D., for material listed in 10 CFR 35.100, 35.200, 35.300 and in vitro studies.
- C. Riaz Tarar, M.D., for material listed in 10 CFR 35.100, 35.200, 35.300 and in vitro studies.
- D. Eugene A. White, M.D., for material listed in 10 CFR 100, 35.200 and in vitro studies.
- E. Robert Benyo, M.D., for in vitro studies.
- F. Ronald A. Siwik, M.D., for material listed in 10 CFR 35.100, 35.200, 35.300 and in vitro studies.
- G. Robert P. Jacobson, M.D., for material listed in 10 CFR 35.100, 35.200, 35.300 (except Iodine-131 for thyroid carcinoma) and in vitro studies.
- H. Howard Potash, M.D., for material listed in 35.100, 35.200, and 35.300.
- I. Bradley Arthur Blackgurn, M.D., for material listed in 35.100, and 35.200.
- J. David Wymer, M.D., for material listed in 35.100, 35.200 and 35.300.
- K. Bon Chul Koo, M.D., for material in 10 CFR 35.100 and 35.200 (excluding generators).

13. This license is based on the licensee's statements and representations listed below:

- A. Application dated February 21, 1994.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date May 25, 1994

By

L. J. D. WATSON
Materials Licensing Section, Region III

COPY

DATE: 2-28-97

CORRESPONDENCE CLARIFICATION SHEET

REVIEWER: BJ HOLT
LICENSEE: Debra
LICENSE NUMBER: 34-1565401

The following correspondence has been received from the above licensee and it is not clear what action(s) is(are) required: Please review this correspondence and indicate which of the following applies, and please return to Debbie Hersey, as soon as possible.

☐ Additional Information to Control No. _____
Process in as a new action, additional information, and no fee required.

☐ Process as new licensing action. Review has already been started on Control No. _____ and this information cannot be combined with current in-house action.

☐ Can be combined with Control No. _____. Review has not started.

☐ Appears to be information for the license file - file it.

☐ Licensee is adding Nuclear Pharmacists.

☐ Amendment is necessary _____. Amendment is not necessary _____.
(Information for license file)

☒ Licensee is adding authorized users.

☒ A check is included ☒. No check is included _____.
Amendment is necessary _____. Amendment is not necessary _____.
(This is a Notification) 50

☐ Process in as a new licensing action:

- A. Amendment _____
B. Renewal _____
C. New License Application _____

☐ Other: _____

Thank You For Your Help!!!

10/16/96

First National Bank of Northwest Ohio
Defiance, Ohio

Defiance Hospital

1206 EAST SECOND STREET
DEFIANCE, OHIO 43512
(419) 783-6955

NO. 112718
112718

DATE
02/07/97

CHECK AMOUNT
*****440.00

FOUR HUNDRED FORTY AND NO/100-----
EXACTLY DOLLARS CENTS VOID AFTER 1 YEAR

PAY TO THE ORDER OF



US NUCLEAR REG COMMISSION

LIC FEE & DEBT COLLECTION

PO BOX 954514

ST LOUIS, MO

63195

⑈112718⑈ ⑆041205291⑆ 6 187 600⑈